Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Charles Omer"'
Autor:
Patrick J. Klein, C. Max Schmidt, Chad A. Wiesenauer, Jennifer N. Choi, Earl A. Gage, Michele T. Yip-Schneider, Eric A. Wiebke, Yufang Wang, Charles Omer, Judith S. Sebolt-Leopold
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 1, Pp 1-8 (2006)
The MEK-ERK growth signaling pathway is important in human hepatocellular carcinoma (HCC). To evaluate the targeting of this pathway in HCC, we characterized a novel, orally-active MEK inhibitor, PD184161, using human HCC cells (HepG2, Hep3B, PLC, an
Externí odkaz:
https://doaj.org/article/1bfd4536e6d74f23b3a58d377eb016b4
Autor:
Yuli Wangab, Keri Van Becelaere, Ping Jiang, Sally Przybranowski, Charles Omer, Judith Sebolt-Leopold
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 7, Iss 4, Pp 336-347 (2005)
PD184352/CI-1040 is a potent and selective MEK1/2 inhibitor that represents the first MEK-targeted agent to enter clinical trials. Here, we report the development and molecular characterization of CI-1040 resistance in the murine colon 26 (C26) carci
Externí odkaz:
https://doaj.org/article/b2b6a25a37cf43719d13564e012ba8a6
Autor:
Patrick A. Zweidler-McKay, Lizhi Zeng, Peter E. Zage, Charles Omer, Kevin Webster, Jeffrey L. Brown, Tao Wang, Ethan Hoffmann, Zhong-Ying Liu, Dave Whitston, Haiyun Wang, Terry MacIntyre, Kenneth Thress
Tropomyosin-related kinases (TrkA, TrkB, and TrkC) are receptor tyrosine kinases that, along with their ligands, the neurotrophins, are involved in neuronal cell growth, development, and survival. The Trk-neurotrophin pathway may also play a role in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d65b0cf23fb0cb49c94c32ad39f481c3
https://doi.org/10.1158/1535-7163.c.6532115
https://doi.org/10.1158/1535-7163.c.6532115
Autor:
Patrick A. Zweidler-McKay, Lizhi Zeng, Peter E. Zage, Charles Omer, Kevin Webster, Jeffrey L. Brown, Tao Wang, Ethan Hoffmann, Zhong-Ying Liu, Dave Whitston, Haiyun Wang, Terry MacIntyre, Kenneth Thress
Supplementary Fig. S3 from Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a818a25db130bda28d45da9b7537835
https://doi.org/10.1158/1535-7163.22485878
https://doi.org/10.1158/1535-7163.22485878
Autor:
Patrick A. Zweidler-McKay, Lizhi Zeng, Peter E. Zage, Charles Omer, Kevin Webster, Jeffrey L. Brown, Tao Wang, Ethan Hoffmann, Zhong-Ying Liu, Dave Whitston, Haiyun Wang, Terry MacIntyre, Kenneth Thress
Supplementary Table S1 from Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2926fae9fcc16d8d8f59959f0274c961
https://doi.org/10.1158/1535-7163.22485872
https://doi.org/10.1158/1535-7163.22485872
La gouvernance des lotissements via les contestations : exemple de la commune de Sèmè-Podji au Bénin
Les opérations de lotissement sont conçues comme des instruments susceptibles de planifier l’utilisation de l’espace et d’améliorer les conditions de vie de la population. Dans la commune de Sèmè-Podji, les processus de mise en œuvre d’
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::629ff21dcd6f95a5ae8d5487509a1e76
http://journals.openedition.org/tem/9080
http://journals.openedition.org/tem/9080
Publikováno v:
Journal of Allergy and Clinical Immunology. 149:AB167
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80d1f50568d261c135ae410e33e97a5e
https://doi.org/10.1016/j.jaci.2021.12.554
https://doi.org/10.1016/j.jaci.2021.12.554
Autor:
Daniel F. Ortwine, Nadia Esmaeil, Haile Tecle, John Quin, Joseph S. Warmus, Michael Kaufman, William A. Denny, Jeffrey F. Ohren, and Alexander G. Pavlovsky, Ronald L. Merriman, Jared B. J. Milbank, Aurash B. Shahripour, Shannon Leigh Black, Judith Sebolt-Leopold, Christopher Whitehead, Julie Ann Spicer, Cathlin Marie Flamme, Heidi S. Camp, Kelley Moore, Richard Gowan, Charles Omer, Mark Stephen Plummer, Sally Pryzbranowski, Gordon W. Rewcastle, Stephen Douglas Barrett
Publikováno v:
Journal of Medicinal Chemistry. 50:5090-5102
A new series of MEK1 inhibitors, the 4-anilino-5-carboxamido-2-pyridones, were designed and synthesized using a combination of medicinal chemistry, computational chemistry, and structural elucidation. The effect of variation in the carboxamide side c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebc469624f4d498f355d1441c78d0b65
https://doi.org/10.1021/jm0704548
https://doi.org/10.1021/jm0704548
Autor:
Charles Omer, Jennifer N. Choi, Yufang Wang, Eric A. Wiebke, Michele T. Yip-Schneider, Judith S. Sebolt-Leopold, Chad A. Wiesenauer, Earl A. Gage, Patrick J. Klein, C. Max Schmidt
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 1, Pp 1-8 (2006)
The MEK-ERK growth signaling pathway is important in human hepatocellular carcinoma (HCC). To evaluate the targeting of this pathway in HCC, we characterized a novel, orally-active MEK inhibitor, PD184161, using human HCC cells (HepG2, Hep3B, PLC, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac18ecd5c67a52eda4852d57656f0fc4
https://doi.org/10.1593/neo.05373
https://doi.org/10.1593/neo.05373
Autor:
Mary Varterasian, Charles Omer, Evanthia Galanis, Scott Wadler, Al B. Benson, Oday Hamid, Paul Bycott, Robert C. Hackman, J. Randolph Hecht, Anthony F. Shields, Margaret Uprichard
Publikováno v:
Journal of Clinical Oncology. 21:1498-1504
Purpose: To evaluate the antitumor activity, safety, immune response, and replication of CI-1042 (ONYX-015), an E1B 55-kd gene-deleted replication-selective adenovirus, administered intravenously to patients with metastatic colorectal cancer Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6799a7a78839df783f1b24e9d08fe522
https://doi.org/10.1200/jco.2003.09.114
https://doi.org/10.1200/jco.2003.09.114